MoonLake Immunotherapeutics - Class A Ordinary Shares (NQ:MLTX)

13.79 -0.04 (-0.29%)

Streaming Delayed Price Updated: 12:17 PM EST, Dec 29, 2025 Add to My Watchlist

Price and Volume

Volume	451,334
Open	13.77
Bid (Size)	13.78 (600)
Ask (Size)	13.80 (200)
Prev. Close	13.83
Today's Range	13.48 - 13.90
52wk Range	5.950 - 62.75
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

MoonLake Immunotherapeutics Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – MLTX

December 15, 2025

From DJS Law Group

Via Business Wire

MOONLAKE DECEMBER 15th DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm

December 15, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Performance

YTD	-74.3%	-74.3%
1 Month	+0.4%	+0.4%
3 Month	+120.8%	+120.8%
6 Month	-70.8%	-70.8%
1 Year	-74.0%	-74.0%

More News

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

December 15, 2025

From Faruqi & Faruqi, LLP

Via Business Wire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 15, 2025

From The Schall Law Firm

Via Business Wire

MOONLAKE CLASS ACTION DEADLINE: Bragar Eagel & Squire, P.C. Urgently Reminds MoonLake Immunotherapeutics Investors to Contact the Firm Before December 15th

December 13, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Deadline Soon: MoonLake Immunotherapeutics (MLTX) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

December 12, 2025

From The Law Offices of Frank R. Cruz

Via Business Wire

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

December 12, 2025

Via TheNewswire.com

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

December 12, 2025

Via NewMediaWire

MLTX DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages MoonLake Immunotherapeutics Investors to Secure Counsel Before Important December 15 Deadline in Securities Class Action – MLTX

December 11, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 11, 2025

From Schall Law

Via GlobeNewswire

MOONLAKE CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics and Encourages Investors to Contact the Firm

December 10, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

MLTX Investor Deadline Alert: MoonLake (MLTX) Class Action Lawsuit – Hagens Berman Scrutinizing Nanobody Superiority Claims After 90% Plunge; December Lead Plaintiff Deadline Looms

December 10, 2025

From Hagens Berman

Via Business Wire

DEADLINE APPROACHING: Berger Montague Advises MoonLake Immunotherapeutics (NASDAQ: MLTX) Investors to Inquire About a Securities Fraud Class Action by December 15, 2025

December 08, 2025

From Berger Montague

Via GlobeNewswire

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

December 08, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 08, 2025

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)

December 05, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

December 04, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 04, 2025

From Schall Law

Via GlobeNewswire

MOONLAKE IMMUNOTHERAPEUTICS (NASDAQ: MLTX) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds MoonLake Immunotherapeutics Investors of Upcoming Deadline

December 03, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Urges Investors of Cepton, and MoonLake to Inquire About Their Rights Before Upcoming Deadlines

December 02, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit with the Schall Law Firm

December 01, 2025

From Schall Law

Via GlobeNewswire

SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against MoonLake Immunotherapeutics (NASDAQ: MLTX)

December 01, 2025

From Bernstein Liebhard LLP

Via GlobeNewswire

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of MoonLake Immunotherapeutics

November 29, 2025

From Faruqi & Faruqi LLP

Via GlobeNewswire

Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash ↗

November 28, 2025

Via The Motley Fool

MLTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman, LLC Announces That MoonLake Immunotherapeutics Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit

November 28, 2025

Via NewMediaWire

Frequently Asked Questions

Is MoonLake Immunotherapeutics - Class A Ordinary Shares publicly traded?

Yes, MoonLake Immunotherapeutics - Class A Ordinary Shares is publicly traded.

What exchange does MoonLake Immunotherapeutics - Class A Ordinary Shares trade on?

MoonLake Immunotherapeutics - Class A Ordinary Shares trades on the Nasdaq Stock Market

What is the ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares?

The ticker symbol for MoonLake Immunotherapeutics - Class A Ordinary Shares is MLTX on the Nasdaq Stock Market

What is the current price of MoonLake Immunotherapeutics - Class A Ordinary Shares?

The current price of MoonLake Immunotherapeutics - Class A Ordinary Shares is 13.79

When was MoonLake Immunotherapeutics - Class A Ordinary Shares last traded?

The last trade of MoonLake Immunotherapeutics - Class A Ordinary Shares was at 12/29/25 12:17 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.